Statin Therapy as a Protective Technique for Potential Cardiovascular Event Occurrences Among Breast Cancer Patients Undergoing Chemotherapy Treatment
OBJECTIVES:
I. Evaluate the feasibility of administering Rosuvastatin to breast cancer patients
undergoing treatment with anthracyclines, paclitaxel, cyclophosphamide, and trastuzumab for
breast cancer.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive rosuvastatin orally (PO) once daily for 3 months in the absence of
disease progression or unacceptable toxicity.
Arm II: Patients receive placebo PO once daily for 3 months in the absence of disease
progression or unacceptable toxicity.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Whether the rate of statin adherence for patients taking chemotherapy is comparable to the rate of adherence found in prior studies (i.e., JUPITER study)
3 months
No
William Hundley
Principal Investigator
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
CCCWFU 98509
NCT01051401
January 2010
Name | Location |
---|---|
Wake Forest University Health Sciences | Winston-Salem, North Carolina 27157 |